Literature DB >> 6186071

Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.

W S Kwee, R W Veldhuizen, R P Golding, H Mullink, J Stam, R Donner, M E Boon.   

Abstract

Thirty men and 7 women with malignant mesothelioma seen at the Free University Hospital from 1st January 1960 until 1st July 1981 were reviewed. The histological, histochemical and morphometrical findings are reported. These findings are compared with 25 cases of pleural metastatic carcinoma and 25 cases of reactive pleural lesions. Fourty-nine percent of malignant mesotheliomas produced hyaluronic acid, however all cases of pleural metastatic carcinomas failed to produce this substance. All cases of malignant mesothelioma were D-PAS negative while 15 cases of pleural metastatic carcinoma showed reactivity to D-PAS. All cases of malignant mesothelioma and 9 cases of metastases were CEA negative. To distinguish malignant mesothelioma from metastases it is advisable to perform the D-PAS staining first. If it is negative mesothelioma can be confirmed by showing hyaluronic acid activity. A positive CEA staining rules out mesothelioma. In our study it was shown that with these methods 18 of 37 mesotheliomas could be identified with certainty, and 22 of the 25 carcinoma metastases. Morphometrically the malignant mesotheliomas could not be distinguished from the metastases, however the reactive pleural lesions had smaller nuclei than the malignant cells with mean values below 30 mu2. In the malignant cases these values had a range from 36 to 101 mu2. In distinguishing between reactive pleural lesions and malignant mesothelioma the production of hyaluronic acid points to the malignant character of the lesion. Thus histochemistry and immunostaining are important in the distinction of malignant mesothelioma from metastases, while the value of morphometry lies mainly in the seperation of reactive lesions from malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6186071     DOI: 10.1007/bf00496570

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN: 0340-1227


  22 in total

1.  A critique of the criteria for the diagnosis of diffuse malignant mesothelioma.

Authors:  M Kannerstein; W T McCaughey; J Churg; I J Selikoff
Journal:  Mt Sinai J Med       Date:  1977 Jul-Aug

2.  Contribution of electron microscopy to the diagnosis of pleural mesothelioma.

Authors:  P Stoebner; J F Bernaudin; M Nebut; F Basset
Journal:  Ann N Y Acad Sci       Date:  1979       Impact factor: 5.691

3.  Electron microscopy in the diagnosis of pleural mesotheliomas.

Authors:  N S Wang
Journal:  Cancer       Date:  1973-05       Impact factor: 6.860

4.  A method for extracting ferruginous bodies from sputum and pulmonary tissue.

Authors:  M J Smith; B Naylor
Journal:  Am J Clin Pathol       Date:  1972-09       Impact factor: 2.493

5.  Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer.

Authors:  T R Harwood; D R Gracey; H Yokoo
Journal:  Am J Clin Pathol       Date:  1976-02       Impact factor: 2.493

6.  Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid.

Authors:  W S Kwee; R W Veldhuizen; C A Alons; F Morawetz; M E Boon
Journal:  Acta Cytol       Date:  1982 Jul-Aug       Impact factor: 2.319

7.  Benign pleural lesion and malignant mesothelioma.

Authors:  M Klima; F Gyorkey
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-11-25

8.  Malignant mesothelioma: a review of 35 cases with diagnosis and prognosis.

Authors:  M H Griffiths; R J Riddell; J M Xipell
Journal:  Pathology       Date:  1980-10       Impact factor: 5.306

9.  Mesothelioma with lung cancer complicating asbestosis.

Authors:  T Okumura; M Okada; M Tsuji; A Inoue; Y Ochiai
Journal:  Acta Pathol Jpn       Date:  1980-07

10.  Cross-reactivity with normal antigens in commercial anti-CEA sera, used for immunohistology. The need for tissue controls and absorptions.

Authors:  M Nap; K A ten Hoor; G J Fleuren
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

View more
  13 in total

1.  Immunohistochemistry in the diagnosis of malignant mesothelioma.

Authors:  M Pfaltz; B Odermatt; B Christen; J R Rüttner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

Authors:  K Sheibani; H Battifora; J S Burke
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

3.  Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.

Authors:  T Kawai; S D Greenberg; L D Truong; C A Mattioli; M Klima; J L Titus
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

4.  Morphometric diagnosis of serous effusions: refinement of differences between benign and malignant cases by use of outlying values and larger sample size.

Authors:  N Scott; J Sutton; C Gray
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

5.  Use of antimesothelial cell antibody and computer assisted quantitative analysis for distinguishing between reactive and neoplastic serosal tissues.

Authors:  A Donna; P G Betta; F Robutti
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

6.  Measuring repeatability and validity of histological diagnosis--a brief review with some practical examples.

Authors:  P B Silcocks
Journal:  J Clin Pathol       Date:  1983-11       Impact factor: 3.411

7.  Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.

Authors:  M L Warnock; A Stoloff; A Thor
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

8.  The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.

Authors:  G A Blobel; R Moll; W W Franke; K W Kayser; V E Gould
Journal:  Am J Pathol       Date:  1985-11       Impact factor: 4.307

9.  Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.

Authors:  R J Marshall; A Herbert; S G Braye; D B Jones
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

10.  Nucleolar and dispersed nucleolar organiser regions (NORs) in differentiating neoplastic from atypical non-neoplastic lesions of the pancreas.

Authors:  M Sato; H Watanabe; Y Ajioka; Y Noda; Y Sakai
Journal:  Gastroenterol Jpn       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.